Good results in Leukemia treatment trials

Israel’s BioSight is pleased with its Phase I/IIa study to evaluate the safety and efficacy of its Astarabine treatment for Acute Myeloid Leukemia (AML) and relapsed/refractory Acute Lymphoblastic Leukemia (ALL).  Full results later this year.  (See also 1st Nov newsletter).

http://www.prnewswire.com/news-releases/biosight-completed-treatment-of-patients-in-astarabine-phase-iiia-clinical-trial-300253764.html

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *